The estimated Net Worth of Richard A Meier is at least $6.67 Millón dollars as of 3 June 2024. Mr. Meier owns over 6,600 units of Intersect ENT Inc stock worth over $3,564,650 and over the last 18 years he sold XENT stock worth over $133,750. In addition, he makes $2,967,680 as Chief Financial Officer y Executive Vice President at Intersect ENT Inc.
Richard has made over 23 trades of the Intersect ENT Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 6,600 units of XENT stock worth $416,460 on 3 June 2024.
The largest trade he's ever made was selling 25,000 units of Intersect ENT Inc stock on 19 May 2016 worth over $133,750. On average, Richard trades about 2,450 units every 71 days since 2006. As of 3 June 2024 he still owns at least 126,227 units of Intersect ENT Inc stock.
You can see the complete history of Mr. Meier stock trades at the bottom of the page.
Richard A. Meier serves as Chief Financial Officer, Executive Vice President of the Company. He has served as our Executive Vice President and Chief Financial Officer since November 2019. From 2013 to 2018, he served as the President – International & Executive Vice President & Chief Financial Officer and senior executive of Owens & Minor, Inc., a global healthcare services company, in which roles he was responsible for managing the global finance, strategic planning and corporate development and pricing functions, and while President – International, managing all aspects of company operations outside the United States, which included the distribution, packaging and products business, as well as global sourcing. Prior to joining Owens & Minor, Mr. Meier served as Executive Vice President and Chief Financial Officer at Teleflex, Inc., a global medical device company, from 2010 to 2012. Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, Inc., a global ophthalmic medical device company, from 2007 to 2009, when the company was acquired as a wholly owned subsidiary of Abbott Laboratories. Mr. Meier joined Advanced Medical Optics as Corporate Vice President and Chief Financial Officer in 2002 and continuously served as Chief Financial Officer while simultaneously performing in a variety of finance and operations roles between 2002 and 2007. Mr. Meier also worked for ICN Pharmaceuticals Inc., now Bausch Health, a global pharmaceutical company, from 1998 to 2002, where he served as Executive Vice President and Chief Financial Officer, and as Treasurer.
As the Chief Financial Officer y Executive Vice President of Intersect ENT Inc, the total compensation of Richard Meier at Intersect ENT Inc is $2,967,680. There are 2 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.
Richard Meier is 60, he's been the Chief Financial Officer y Executive Vice President of Intersect ENT Inc since 2019. There are 6 older and 6 younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt y W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Intersect ENT Inc executives and other stock owners filed with the SEC include: